LUNG CANCER HARB ORING HER2 MUTATION :EPIDE MIOLOGI CAL CHARACTE RISTICS AND
% H; s# s: b% S' UTHERAPE UTIC PERSPECTIVES
+ [4 w2 D: X* t& K( E# s3 b) KJ. Mazieres, S. Peters
* x2 B T* Z H; E+ b% s6 G8 A2 F1 oIntroduction: HER2 oncogene is a memb er of the EGFR family, encoding atransmembrane receptor that drives and regulates cell proliferation. HER2 mutations are identified in about 2% of non small cell lung cancer (NSCLC) , mainly located in exon 20, and appear to be critical for lung cancer carcinogenesis . Very scarce data are available to define a clinical profile of the patients harboring HER2 mutated NSCLC. We aimed to study clinic opatholog ical characteristics an d therapeutic3 c9 S/ ~) Z+ F. Z w6 l
outcomes of patients harboring HER2 mutation in a large European series. Result s:We retrospec tively ide ntified 46 NSCLC patients diagn osed with HER2 exon 20 mut ation. HER2 mutation was mainly exclusive as only one concomitan t KRas mutation was des cribed. Our population was characterized by a median age of 60 yr (31 to 86 yr), a high proportion of women (30 vs. 16 men, 65% ), and of never smokers (24, 52%). All tumors were adenoc arcinomas (two with lepidic features). Half of the patients had stage IV dise ase at the time of diagnosis. HER2 targeted: c& H% o" |- O1 b" k2 X
treatment was delivered after convention al chemothe rapy. A total of 20 anti-Her29 w. R, E$ n8 k( s4 ~
treatments were eval uable. We observed 4 progressive dise ases, 7 disease stabilizations) L8 M& `4 a8 T5 @
and 9 partial resp onses according to RECIST 1.1 (overall response rate ORR = 45% ;
+ u6 ?$ A& U' T, Tdisease control rate DCR = 80%). Specifica lly, we obse rved a DCR of 92% for
) @, A0 y, d$ D3 }# D* Etrastuzum ab-based therapie s (n = 14), 100 % for afatinib (n = 3) but no response to+ q, P( \9 Z$ z8 K1 ]) Y
lapatinib (n = 2) and to a multiTKI (n = 1). Median survival was of 68.2 months and
9 o! O, k' r! j5 u# {22.9 months for respectively early stage and stag e IV patients.
( R& S- y$ U* L- q" Z9 TConclusion: This study, the largest to date dedic ated to HER2 mutated NSCLC,& S9 S% | \8 s. u. N- O$ C
reinforces the importance of an HER2 screening strategy in lung adenoc arcinomas .
9 i. r5 M$ P3 D9 j5 cHER2-target ed drugs shou ld be tested further, ide ally withi n large collaborative
3 c) L0 ]1 z( o: p0 `' `: D* \clinicaltrials.
K: m2 M4 {3 B. ]- t |
显身卡
